Kura Oncology’s (KURA) “Buy” Rating Reaffirmed at TD Cowen

TD Cowen reaffirmed their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a report released on Thursday morning,Benzinga reports.

Other equities research analysts have also issued reports about the company. Lifesci Capital raised Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. JMP Securities reiterated a “market outperform” rating and issued a $32.00 target price on shares of Kura Oncology in a report on Tuesday. Wedbush restated an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a report on Monday, November 4th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research note on Thursday. Finally, HC Wainwright increased their target price on Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a report on Thursday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.38.

Kura Oncology Price Performance

NASDAQ:KURA traded up $0.86 during trading hours on Thursday, reaching $10.92. 1,415,129 shares of the company’s stock were exchanged, compared to its average volume of 965,695. The company has a market capitalization of $849.18 million, a P/E ratio of -4.63 and a beta of 0.86. Kura Oncology has a 12 month low of $9.06 and a 12 month high of $24.17. The business’s 50-day simple moving average is $18.28 and its two-hundred day simple moving average is $19.82. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02.

Institutional Investors Weigh In On Kura Oncology

Several large investors have recently made changes to their positions in the company. Avoro Capital Advisors LLC boosted its holdings in Kura Oncology by 29.2% in the first quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock worth $82,120,000 after purchasing an additional 870,000 shares in the last quarter. Suvretta Capital Management LLC boosted its stake in shares of Kura Oncology by 8.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock worth $149,535,000 after acquiring an additional 583,155 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Kura Oncology by 50.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after acquiring an additional 577,732 shares during the last quarter. Sofinnova Investments Inc. raised its stake in shares of Kura Oncology by 64.4% in the 2nd quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock valued at $16,992,000 after acquiring an additional 323,303 shares in the last quarter. Finally, Armistice Capital LLC raised its stake in shares of Kura Oncology by 14.7% in the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after acquiring an additional 302,000 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.